FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 足夠公眾持股量的確認(註4) 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Core Insights - Alibaba Health's AI product "Hydrogen Ion" has established a content collaboration with the People's Medical Publishing House, gaining systematic access to its core medical publishing resources [1] - The collaboration aims to transform static medical content into a dynamic, intelligent knowledge system that supports doctors in obtaining precise clinical advice and drug information through natural language queries [1][2] Group 1: Collaboration and Technology - The partnership with the People's Medical Publishing House allows Hydrogen Ion to utilize a comprehensive clinical knowledge base and drug knowledge base, constructed from thousands of textbooks, guidelines, and monographs [1] - AI technologies such as knowledge graphs, natural language retrieval, and dynamic evidence positioning will enable authoritative knowledge sourcing for medical professional Q&A [1][2] Group 2: Practical Applications - Hydrogen Ion can provide evidence-based, high-quality professional support for clinical decision-making by generating answers to specific medical queries and citing the source of information [2] - The AI assistant is designed to meet the real needs of clinical practice, research, and education, enhancing its evidence-based capabilities in various medical scenarios [2] Group 3: Future Directions - The company plans to deepen collaborations with national medical publishing or academic institutions to further advance the usability and reliability of authoritative medical knowledge [2] - The goal is to transition medical knowledge from being merely readable to being usable, verifiable, and dependable, ultimately serving as a comprehensive AI tool for doctors [2]

每经AI快讯，2月2日，港股明星科网股震荡走低，哔哩哔哩、百度、阿里健康等多股跌超5%，网易- S、阿里巴巴、腾讯控股、京东等个股跟跌。 ...

Core Insights - Alibaba Health's AI product "Hydrogen Ion" has partnered with the Chinese Medical Association to integrate top-tier medical resources into its platform, enhancing the accessibility and usability of authoritative medical knowledge for clinicians and researchers [1][2] - The collaboration aims to convert medical academic resources into a structured knowledge system that supports precise sourcing and retrieval, addressing challenges faced by doctors in keeping up with rapid updates and finding reliable information [1] Group 1 - The partnership will enable doctors to ask natural language questions and receive immediate answers based on the latest evidence-based guidelines, along with precise citations for reference [1] - Researchers will benefit from intelligent cross-journal and cross-disciplinary searches, improving knowledge association and retrieval capabilities [1] - The Chinese Medical Association's clinical guidelines and expert consensus are considered industry "gold standards," providing invaluable guidance to frontline clinical and research doctors [1] Group 2 - The Director of the New Media Department of the Chinese Medical Association expressed optimism about the collaboration, highlighting the new evidence-based information paradigm that Hydrogen Ion will provide to doctors [2] - Hydrogen Ion focuses on addressing the real needs of doctors in clinical and research settings, aiming to enhance its core functionalities in evidence support, intelligent retrieval, and literature review [2] - The goal is to ensure that doctors receive accurate answers backed by evidence in their clinical and research endeavors [2]

Group 1 - Bayer's oral contraceptive Youshuai® 84-pack has successfully completed import clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's long-term health management [1] - The "Consensus on Clinical Application of Combined Oral Contraceptives in China" has been initiated, focusing on improving women's awareness of the importance of medication adherence in disease management [3] - The low usage rate of combined oral contraceptives (COC) among women of childbearing age in China is attributed to fear of hormonal drugs and insufficient understanding, leading to missed opportunities for effective health benefits [3] Group 2 - Youshuai® is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, suitable for contraception and treatment of moderate acne in females aged 14 and above [3] - The launch of Youshuai® 84-pack is expected to reduce the frequency of medication purchases and improper discontinuation, thereby enhancing patient adherence and continuity of treatment [3] - Alibaba Health provides a comprehensive online healthcare service system, ensuring convenient access to medications and maintaining treatment continuity through efficient nationwide delivery [4]

Core Insights - Bayer's oral contraceptive Youshu Yue in a 84-tablet pack has successfully completed import customs clearance and is launched on Alibaba Health, aiming to enhance medication convenience and adherence for women's health management [1][3] - The launch coincides with the initiation of the "Consensus on Clinical Application of Combined Oral Contraceptives in China," which emphasizes the importance of medication adherence in disease management for women [3] Group 1: Product Launch and Features - Youshu Yue is designed to cover a complete three-month medication cycle, addressing the actual needs of long-term health management for women [1] - The product is a short-acting oral contraceptive approved in China since December 2014, featuring a "24+4" dosing regimen, which includes 24 active tablets and 4 inactive tablets [3] - It is indicated for contraception and treatment of moderate acne in females aged 14 and above without known contraindications for oral contraceptives [3] Group 2: Market Context and Challenges - The usage rate of combined oral contraceptives (COCs) among women of childbearing age in China is notably low, primarily due to fears of hormonal medications and insufficient understanding of COCs [3] - The lack of awareness leads to underutilization of COCs, which can provide both contraceptive and non-contraceptive health benefits [3] Group 3: Service and Distribution - Alibaba Health serves as a platform for the launch, providing a comprehensive online healthcare service system, including professional pharmacist reviews and medication guidance [4] - The platform addresses the inconvenience of purchasing medications due to time and geographical limitations, ensuring continuity of treatment through efficient nationwide delivery [4]

本报讯 （记者袁传玺）1月29日，拜耳原研口服避孕药优思悦®84片装大包装首批药品顺利完成进口通关，率先在阿里健 康首发，该规格于第八届中国国际进口博览会首次亮相，旨在覆盖三个月完整的用药周期，提升用药的便利性和依从性，更好 地契合女性健康长周期管理的实际需求。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的慢性病患者，经专业医 生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦因购药不及时而中断，往往会影响疗效。优思 悦®84片装的推出，有助于减少频繁购药和不当停药的情况，提升患者依从性和用药连续性，为临床实践和患者管理提供了更 为便利的选择。" 优思悦®（屈螺酮炔雌醇片Ⅱ）是一种短效口服避孕药，2014年12月份在中国获批上市，是中国首个采用"24+4"给药模式 的复方口服避孕药，24片活性药片（每片含0.02mg炔雌醇和3mg屈螺酮）加4片无活性药片，适用于女性避孕，及≥14岁、没有 口服避孕药已知禁忌的已初潮女性的中度寻常痤疮治疗，只有在患者希望使用口服避孕药作为避孕措施时才能使用本品治疗痤 疮。优思悦®通过调节激素水平辅助治疗痤疮，通常至少 ...

Core Viewpoint - Alibaba Health's stock rose nearly 4%, reaching HKD 6.92 with a trading volume of HKD 506 million, following the launch of its AI medical application "Hydrogen Ion" with a new feature for "dynamic evidence positioning" [1] Group 1: Product Development - The "Hydrogen Ion" application now includes a feature that accurately identifies specific statements in original texts, verifying their timeliness, authority, and logical consistency [1] - This upgrade enhances the previous method of vague citations in AI responses to a precise identification of statements and their credibility [1] - The product has completed internal testing and is now available for download, targeting doctors in clinical and research fields [1] Group 2: Market Position and Outlook - CITIC Securities highlights that leading pharmaceutical e-commerce platforms, including Alibaba Health and JD Health, have launched AI medical applications aimed at doctors [1] - The report expresses optimism about these platforms leveraging resources from upstream pharmaceutical companies and downstream end-users, along with their parent companies' AI capabilities, to excel in the ToD AI medical application sector [1] - The expectation is that these companies will successfully establish a commercial model that enhances revenue through AI medical applications [1]

Core Viewpoint - Alibaba Health's stock rose nearly 4%, reaching HKD 6.92 with a trading volume of HKD 506 million, following the launch of its AI medical application "Hydrogen Ion" with a new feature for "dynamic evidence positioning" [1] Group 1: Product Development - The "Hydrogen Ion" application now offers precise citation of information, enhancing the reliability and timeliness of AI-generated responses, moving from vague references to specific statements [1] - The product has completed internal testing and is now available for download, targeting doctors in clinical and research fields [1] Group 2: Market Position and Outlook - CITIC Securities highlights that leading pharmaceutical e-commerce platforms like Alibaba Health and JD Health are launching AI medical applications for doctors [1] - The report expresses optimism about these platforms leveraging their resources from upstream pharmaceutical companies and downstream consumers, along with their parent companies' AI capabilities, to excel in the ToD AI medical application sector and successfully establish a commercial model [1]

Core Insights - Alibaba Health's medical AI application "Hydrogen Ion" has launched a key version update featuring a new function called "Dynamic Evidence Localization" which allows precise identification of specific statements supporting claims, while also verifying their timeliness, authority, and logical consistency [2] Group 1: Dynamic Evidence Localization - The new function upgrades traditional "static citation" methods to "living evidence," addressing the industry's challenge of determining whether information is still valid and credible [2] - The system integrates timeliness and authority into its citation logic, continuously updating and filtering global guidelines and literature to ensure responses are based on the latest and most reliable medical evidence [2][3] Group 2: User Experience and Impact - When users inquire about specific clinical trial data, the system provides structured medical conclusions with citation tags, allowing seamless tracing back to original literature and supporting statements [3] - This technology significantly reduces the information verification cost for clinical and research work, enabling doctors to make decisions without pausing to check original documents, as the AI performs triple verification of effectiveness, authority, and logical consistency [3]